天津力生制药股份有限公司 总经理办公会议事规则 天津力生制药股份有限公司总经理办公会议事规则 （2026 年 1 月修订） 第一章 总则 第一条 按照健全现代企业制度的要求，为进一步完善公司法人治理结构，规范经理层 人员有效履行职责，提高办事效率，根据《中华人民共和国公司法》和《天津力生制药股 份有限公司章程》《天津力生制药股份有限公司"三重一大"决策制度实施办法》，结合公司 实际，制定本规则。 第二条 党委会研究讨论是经理层决策重大问题的前置程序，重大经营管理事项必须经 党委会研究讨论后，由经理层作出决定。未经党委会研究讨论的重大事项，经理层不能决 策，确保党委会作用在决策层、执行层、监督层得到有效发挥。 第二章 会议召开 第三条 总经理办公会由总经理召集和主持。总经理因故不能出席会议时，由其委托一 名副总经理召集和主持。 第四条 总经理办公会分为例会和临时会议。例会原则上每月召开不少于一次，临时会 议根据工作需要安排。有下列情况之一时，应及时召开总经理办公会： （一）董事长提议时； （二）总经理认为必要时； （三）有重要事项必须立即决定时； （四）有突发性事件发生时。 第五条 出席人员半数以上参加方能召开 ...

天津力生制药股份有限公司 重大事项内部报告办法 （2026 年 1 月修订） 第一章 总 则 天津力生制药股份有限公司重大事项内部报告办法 第一条 为规范天津力生制药股份有限公司（以下简称"公司"）的重大事项报告工作的管理， 明确公司各部门、各控股公司、参股公司的重大事项收集、报告和管理办法，保证公司及时、 准确、全面、完整地披露信息，根据《中华人民共和国证券法》《深圳证券交易所股票上市规 则》及其他有关法律、法规、规范性文件和《公司章程》的规定，结合本公司实际情况，特制 订本办法。 第二条 本办法适用于公司、公司各部门、控股子公司、公司持股5%以上的股东及其一致 行动人、公司能够对其实施重大影响的参股公司以及有可能接触相关信息的相关人员。 第二章 一般规定 第三条 公司重大事项内部报告办法是指当出现、发生或即将发生可能对公司股票及其衍生 品种的交易价格产生较大影响的事项时，按照本办法相关规定负有报告义务的单位、部门和人 员（以下简称"报告义务人"），应及时将相关事项向公司董事会和董事长报告的办法。 第四条 公司重大事项报告义务人包括： （一）公司董事、高级管理人员和各部门负责人； （二）公司全资（控股）子公 ...

证券代码：002393 证券简称：力生制药 公告编号：2026-003 天津力生制药股份有限公司 关于召开2026年第一次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东会届次：2026年第一次临时股东会 2、会议召集人：公司董事会，本次股东会经公司第八届董事会第三次会议决议召开。 3、会议召集、召开的合法、合规性：本次股东会会议召集、召开符合有关法律、行政 法规、部门规章、规范性文件和公司章程的规定。 4、会议召开时间： 现场会议召开时间：2026年2月2日（星期一）下午3:30开始 网络投票时间为：2026年2月2日，其中通过深圳证券交易所交易系统进行网络投票的 具体时间为2026年2月2日上午9:15—9:25,9:30—11:30和13:00—15:00；通过深圳证券交易 所互联网投票系统进行网络投票的具体时间为2026年2月2日9:15～15:00期间的任意时间。 5、股权登记日：2026年1月26日（星期一） 6、会议召开地点：天津力生制药股份有限公司会议室 天津市西青经济技术开发区赛达北一道16号 ...

证券代码：002393 证券简称：力生制药 公告编号：2026-002 天津力生制药股份有限公司 第八届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 天津力生制药股份有限公司(以下简称"公司"或"本公司")于2026年1月8日以书面方式发 出召开第八届董事会第三次会议的通知，会议于2026年1月15日以通讯表决方式召开。会议 应参加的董事9名，实际参加的董事9名，符合《公司法》及《公司章程》的规定。 二、董事会会议审议情况 1、会议以9票同意、0票反对、0票弃权的表决结果，审议通过了《关于2025年前三季 度利润分配的预案》。 公司拟向全体股东每10股派发现金红利人民币3.00元（含税），不送红股，不以资本公 积金转增股本。以截至本次董事会日（2026年1月15日）的公司总股本257,616,859股，扣 除回购专用账户699,980股和正在办理注销手续的股权激励限售股30,016股，即以 256,886,863股为基数计算，2025年前三季度拟派发现金红利人民币77,066,058.90元（含 税）。 具体 ...

证券代码：002393 证券简称：力生制药 公告编号：2026-004 2025年1-9月，公司合并报表归属于母公司股东的净利润为37,074.04万元, 母公司实现 净利润为7,416.05万元。截至2025年9月30日，公司合并报表期末未分配利润为173,637.04 万元，母公司累计可供分配利润为125,184.63万元。以上数据均未经审计。 根据公司的实际情况和股利分配政策，公司拟向全体股东（公司回购专用证券账户除外） 每10股派发现金红利人民币3.00元（含税），不送红股，不以资本公积金转增股本。截至2026 年1月15日，公司总股本257,616,859股，扣除回购专用账户699,980股和正在办理注销手续 的股权激励限售股30,016股，即以256,886,863股为基数计算2025年前三季度拟派发现金红 利人民币77,066,058.90元（含税）。 若在方案实施前由于股份回购、股权激励行权等原因而引起总股本变化的，则以未来实 施分配方案时股权登记日的可分配股份总数为基数，利润分配按照每股分配比例不变的原则 相应调整分配总额。 二、现金分红方案合理性说明 公司2025年前三季度利润分配预案是基 ...

Core Viewpoint - The company has announced the details of its 2024 restricted stock incentive plan, including the grant date, number of shares, and pricing, which aims to motivate and retain key personnel through equity incentives [2][4][7]. Group 1: Incentive Plan Details - The grant date for the restricted stock is set for December 5, 2025, with the registration completion date on January 9, 2026 [2][22]. - A total of 740,000 shares will be granted, representing 0.2872% of the company's total share capital prior to the grant [2][7]. - The grant price for the restricted stock is set at 10.24 yuan per share [2][7]. Group 2: Approval Process - The company held several meetings to approve the incentive plan, including the seventh board meeting on December 20, 2024, and the first extraordinary general meeting of shareholders on February 5, 2025 [3][4][5]. - The plan has undergone verification by the supervisory board and independent financial advisors, ensuring compliance with relevant regulations [3][5][7]. Group 3: Stock Repurchase and Impact - The restricted stock is sourced from shares repurchased from the secondary market, with a total of 7,209,980 shares repurchased, accounting for 2.80% of the company's total share capital [25][24]. - The stock repurchase was conducted at prices ranging from 17.28 yuan to 18.50 yuan per share, with a total expenditure of approximately 129.41 million yuan [25]. Group 4: Performance Assessment and Conditions - The incentive plan includes performance assessment criteria that must be met for the release of the restricted stock, with evaluations conducted annually over three accounting years [15][19]. - Individual performance assessments will be tailored to different roles, with a grading system to determine eligibility for stock release [19][20]. Group 5: Financial Implications - The issuance of restricted stock will not change the total share capital, thus not affecting the earnings per share [23]. - The company will account for the costs associated with the restricted stock in accordance with relevant accounting standards, adjusting for the number of shares eligible for release based on performance metrics [24][25].

证券代码：002393 证券简称：力生制药 公告编号：2026-001 天津力生制药股份有限公司 关于2024年限制性股票预留部分授予登记完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 重要内容提示： 1.限制性股票预留部分授予日：2025年12月5日 2.限制性股票授予登记完成时间：2026年01月09日 3.限制性股票授予数量：74万股，占授予前公司总股本的比例为0.2872% 4.限制性股票授予登记人数：22人 5.限制性股票来源：从二级市场回购的公司A股普通股股票 6.限制性股票授予价格：10.24元/股 根据天津力生制药股份有限公司(以下简称"力生制药""本公司"或"公司")2025 年第一次临时股东大会授权，公司于2025年12月5日召开第八届董事会第二次会议，审议通 过了《关于调整2024年限制性股票激励计划授予价格暨向激励对象授予预留部分限制性股 票的议案》。根据中国证券监督管理委员会《上市公司股权激励管理办法》、深圳证券交易 所、中国证券登记结算有限责任公司深圳分公司有关规则的规定，公司已完成2024年限制 性股票激励计划（以下简 ...

Core Viewpoint - The article highlights the evolution and modernization of Lisheng Pharmaceutical, emphasizing its commitment to public health and innovation while maintaining its historical roots through the "Three Fish" brand established in 1930 [1][2]. Group 1: Company History and Philosophy - Lisheng Pharmaceutical was founded in 1930 to address the lack of affordable medicine for the public, with the "Three Fish" trademark symbolizing its commitment to making medicine accessible [2]. - The company's philosophy of "for the people" has been a guiding principle, focusing on the integration of raw materials and formulations to ensure affordability and availability of medications [2]. Group 2: Innovation and Product Development - Lisheng has increased its R&D investment, with over 8% of its budget allocated to research in the first half of 2025, resulting in the approval of key products and multiple patent applications [3]. - The company is focusing on high-end generic drugs, modified new drugs for specific populations, and original innovations in critical areas such as synthetic biology and gene therapy [3]. Group 3: Brand Modernization and Marketing Strategy - The "Three Fish" brand has been revitalized to resonate with younger consumers, incorporating cultural narratives and modern marketing strategies such as short online dramas to enhance brand visibility [4][6]. - Lisheng has developed a multi-channel marketing network, utilizing OTC, medical, and online platforms to reach diverse consumer groups effectively [6][7]. - The "Shoubi Mountain" brand is transitioning from a single product to a comprehensive series of antihypertensive medications, with plans to expand its product range significantly [7].

Group 1 - The flu epidemic in China is at a high level, primarily driven by the H3N2 strain, with increased transmission risk due to upcoming population movements during the New Year holiday [1] - Demand for antiviral and symptomatic medications has surged, with a reported over 500% increase in flu-related drug purchases on Alibaba Health and over 100% increase in orders for traditional Chinese medicine on Meituan [1] - The pharmaceutical industry is responding effectively across the supply chain, from vaccine production to drug distribution, indicating a well-coordinated effort to manage the public health challenge [1][2] Group 2 - Vaccine companies are ramping up production, with Hualan Vaccine reporting 55 batches of flu vaccine issued since November, reflecting increased public willingness to get vaccinated [2] - Diagnostic companies like Dian Diagnostics and Kingmed Diagnostics are seeing increased business, supporting the trend of testing before treatment, which enhances rational drug use [2] - The treatment landscape is diversifying, with both chemical and traditional Chinese medicines being utilized, indicating a shift in market dynamics [3][5] Group 3 - Traditional Chinese medicine is gaining traction, with companies like China Resources Sanjiu and Kangyuan Pharmaceutical seeing strong growth in their antiviral product lines [5] - The distribution sector is crucial, with companies like Yiyigou ensuring rapid delivery of essential medications during peak demand periods [5] - The clinical relevance of traditional Chinese medicine is increasing, supported by government policies that endorse its use in flu treatment, leading to a rise in evidence-based research [6][9] Group 4 - Companies are focusing on clinical research to validate the efficacy of traditional Chinese medicines, with Kangyuan Pharmaceutical conducting head-to-head trials against conventional drugs [7][9] - The competitive landscape in the respiratory system traditional Chinese medicine market is diverse, with companies like China Resources Sanjiu and Yiling Pharmaceutical leveraging brand strength and market recognition [9] - As the industry moves towards evidence-based medicine, companies with strong research capabilities and clinical data are likely to capture more market opportunities [9]

Core Viewpoint - On December 30, a total of 7 listed companies will have their restricted shares unlocked, with a total market value of approximately 11.55 billion yuan [1]. Group 1: Company Specifics - Lisheng Pharmaceutical (Stock Code: 002393) will unlock 497,000 shares under equity incentive restrictions [1]. - Xuefeng Technology (Stock Code: 603227) will unlock 97.6172 million shares from the issuance of A-shares to institutional investors [1]. - Su Yan Jingshen (Stock Code: 603299) will unlock 622,700 shares under equity incentive restrictions [1]. - Qianhe Flavoring (Stock Code: 603027) will unlock 2.043 million shares under equity incentive restrictions [1]. - Hongming Co., Ltd. (Stock Code: 301105) will unlock 3.375 million shares from pre-issuance restrictions [1]. - Fulede (Stock Code: 301297) will unlock 200 million shares from pre-issuance restrictions [1]. - Baiwei Storage (Stock Code: 688525) will unlock 11.4 million shares [1].